Cargando…
Inhibitory effect of the novel tyrosine kinase inhibitor DCC-2036 on triple-negative breast cancer stem cells through AXL-KLF5 positive feedback loop
Triple-negative breast cancer (TNBC), an aggressive histological subtype of breast cancer, exhibits a high risk of early recurrence rate and a poor prognosis, and it is primarily associated with the abundance of cancer stem cells (CSCs). At present, the strategies for effectively eradicating or inhi...
Autores principales: | Shen, Yingying, Zhu, Qingyun, Xiao, Maoyu, Yin, Liyang, Feng, Wenjie, Feng, Jianbo, He, Jun, Li, Pei, Chen, Xiguang, Ding, Wenjun, Zhong, Jing, Zeng, Zhaolin, Xie, Zhuoye, Liu, Jianghua, Zu, Xuyu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9428169/ https://www.ncbi.nlm.nih.gov/pubmed/36042208 http://dx.doi.org/10.1038/s41419-022-05185-x |
Ejemplares similares
-
The Conformational Control Inhibitor of Tyrosine Kinases DCC-2036 Is Effective for Imatinib-Resistant Cells Expressing T674I FIP1L1-PDGFRα
por: Shen, Yingying, et al.
Publicado: (2013) -
Self-Renewal Signalling Pathway Inhibitors: Perspectives on Therapeutic Approaches for Cancer Stem Cells
por: Zhu, Qingyun, et al.
Publicado: (2020) -
Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia
por: Cortes, Jorge, et al.
Publicado: (2017) -
Tumor-Associated Macrophages: Critical Players in Drug Resistance of Breast Cancer
por: Xiao, Maoyu, et al.
Publicado: (2021) -
PROJECT ADMINISTRATION AGREEMENT KN2036/DG
por: THE EUROPEAN ORGANIZATION FOR NUCLEAR RESEARCH, CERN, et al.
Publicado: (2012)